Eminence Capital, LP Exact Sciences Corp Transaction History

Eminence Capital, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$35.61 - $76.23 $7.92 Million - $16.9 Million	222,278 Added 9.89%	2,469,746 $97.3 Million
Q1 2022 May 16, 2022	SELL	$57.56 - $82.54 $32,060 - $45,974	-557 Reduced 0.02%	2,247,468 $157 Million
Q4 2021 Feb 14, 2022	BUY	$72.5 - $100.68 $60.5 Million - $83.9 Million	833,812 Added 58.96%	2,248,025 $175 Million
Q3 2021 Nov 15, 2021	BUY	$90.24 - $124.05 $28.7 Million - $39.4 Million	317,900 Added 29.0%	1,414,213 $135 Million
Q2 2021 Aug 16, 2021	BUY	$93.66 - $139.27 $32.4 Million - $48.2 Million	346,225 Added 46.16%	1,096,313 $136 Million
Q1 2021 May 17, 2021	SELL	$116.57 - $155.01 $22.4 Million - $29.7 Million	-191,770 Reduced 20.36%	750,088 $98.8 Million
Q4 2020 Feb 16, 2021	SELL	$99.61 - $142.12 $39.3 Million - $56.1 Million	-394,897 Reduced 29.54%	941,858 $125 Million
Q3 2020 Nov 16, 2020	BUY	$72.92 - $102.01 $14.3 Million - $20 Million	196,045 Added 17.19%	1,336,755 $136 Million
Q2 2020 Aug 17, 2020	BUY	$55.75 - $92.75 $44.7 Million - $74.4 Million	802,114 Added 236.89%	1,140,710 $99.2 Million
Q1 2020 May 15, 2020	BUY	$37.9 - $104.44 $12.8 Million - $35.4 Million	338,596 New	338,596 $19.6 Million

673

162M

2.58M

2.19M

Ticker EXAS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 176,960,000
Market Cap $10.3B
Description
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...

Get notified when there are updates to the investment portfolio of Eminence Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Eminence Capital, LP with notifications on news.